The approval of the IND application for the therapy will initiate the launch of Parkinson's clinical trials in the U.S. A multi-center, placebo-controlled, Phase 2A trial (NCT) of TB006 in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback